Alzheimer’s disease: The right drug, the right time
In the journal Science, MBI leaders Drs. Steven DeKosky and Todd Golde discuss the challenges of developing effective Alzheimer's therapies and the road ahead.
In the journal Science, MBI leaders Drs. Steven DeKosky and Todd Golde discuss the challenges of developing effective Alzheimer's therapies and the road ahead.
Study demonstrates that additional proteins misfold in the presence of neurodegenerative disease pathologies.
Following Sandra Day O'Connor's announcement of her dementia, and possibly Alzheimer's, diagnosis, Dr. Todd Golde explains a dementia diagnosis, current treatments and his hope for the future.
A mouse-model study led by Drs. Paramita Chakrabarty and Todd Golde describes how their team bioengineered a naturally occurring protein to enable it to bind to amyloid beta protein in the brain.
The vulnerability of particular brain regions in old age that are important for problem-solving and reasoning.
MBI members discuss how the service and science hub specialty care model is working at the Fixel Center.
Glenn Smith, Ph.D., ABPP-cn, chair of the department of clinical and health psychology, recently commented on the state of Alzheimer's disease research in a Citrus County Chronicle feature story.
Visit Drs. Todd Golde and Brenda Moore's Reddit Science AMA from Jan. 31, where they answered questions about the future of Alzheimer's research.
Neuroscientists at UF's McKnight Brain Institute have validated a potential pathway to halt the progression of Alzheimer’s disease.
Dr. Anthony Yachnis explains the importance of brain donation and how the work done at the McKnight Brain Institute of the University of Florida Neuromedicine Brain Bank advances research.